Abstract: Disclosed are novel physiologically active substance SS 12538, process for its preparation and a novel microorganism producing the same.The novel physiologically active substance SS 12538 is represented by the following formula (I): ##STR1## in which R represents a hydrogen atom, a methyl group or an ethyl group. SS 12538 is obtained by inoculating a novel strain S 12538 in a nutrient-containing medium and cultivating aerobically.SS 12538 has excellent vasodilating action and antibiotic action against a certain gram positive bacteria and dermatophytes.

Abstract: Disclosed herein are Fredericamycin A derivatives, each, represented by the following general formula (I): ##STR1## wherein R means a hydrogen atom or acyl group, A denotes ##STR2## and dotted bonds are optional, with a proviso that when A is ##STR3## or the dotted bonds are contained, R is other than hydrogen atom. They have excellent antibacterial and antitumor activities and at the same time, are extremely stable compared with Fredericamycin A.

Abstract: An immunoactivator comprising an effective amount of a thiazolobenzoxazine derivative of the formula, or its salt ##STR1## wherein R.sup.1 represents a hydrogen atom, carboxyl group or lower alkoxycarbonyl group, R.sup.2 represents a substituted or unsubstituted phenyl group, lower alkyl group or furyl group, and R.sup.3 represents a hydrogen atom or lower alkoxy group.

Abstract: Novel phenylacetic ester derivatives (I) ##STR1## are produced by reacting ketoprofene with alkylene glycol compounds. The derivatives (I) are useful as a nonsteroidal antiphlogistic and analgesic agent with very reduced side effects comparing with sole use of ketoprofene.

Abstract: The specification describes an antiulcer drug containing as an active ingredient a 2,3-butanediol diester derivative represented by the formula (I): ##STR1## where R.sub.A may for example be a saturated or unsaturated alkyl or styryl group and R.sub.B may for example be a saturated or unsaturated alkyl, phenyl, phenylalkyl, phenylpropenyl or phenoxyalkyl group. These groups may optionally be substituted. Many of 2,3-butanediol diester derivatives embraced by the formula (I) are novel. Also described are a novel process for preparing such novel 2,3-butanediol diester derivatives. The 2,3-butanediol diester derivatives of the formula (I) has an action to depress strongly the growth of peptic ulcer and has a very low toxicity.

Abstract: An antiulcer drug comprising Ikarugamycin as its active ingredient is disclosed.

Abstract: The specification describes as antiulcer drug containing as an active ingredient a 2,3-butanediol diester derivative represented by the formula (I): ##STR1## where R.sub.A may for example be a saturated or unsaturated alkyl or phenyl styryl group and R.sub.B may for example be a saturated or unsaturated alkyl, phenyl, phenylalkyl, phenylpropenyl or phenoxyalkyl group. These groups may optionally be substituted. Many of 2,3-butanediol diester derivatives embraced by the formula (I) are novel. Also described are a novel process for preparing such novel 2,3-butanediol diester derivatives. The 2,3-butandiol diester derivatives of the formula (I) has an action to depress strongly the growth of peptic ulcer and has a very low toxicity.

Abstract: The specification describes novel thiazinobenzimidazole derivatives represented by the general formula: ##STR1## wherein R.sub.1, R.sub.2 and X represent a wide variety of substituent groups respectively. The above thiazinobenzimidazole derivatives may be prepared by reacting corresponding 2-hydroxymethyl thiazinobenzimidazole derivatives with corresponding reactive derivatives of carboxylic acid or halogenide or by reacting 2-p-toluenesulfonyloxymethyl-thiazinobenzimidazole derivatives with sodium azides, thiols, phenols or amines. The above thiazinobenzimidazole derivatives wherein X is OH may be prepared by reducing their corresponding 2-alkoxycarbonyl derivatives. Where X represents a p-toluenesulfonyloxy group, the thiazinobenzimidazole derivatives may be obtained by reacting corresponding 2-hydroxymethyl-thiazinobenzimidazole derivatives with p-toluenesulfonyl chloride.

Abstract: The specification describes novel thiazinobenzmidazole derivatives represented by the general formula: ##STR1## wherein R.sub.1, R.sub.2 and X represent a wide variety of substituent groups respectively. The above thiazinobenzimidazole derivatives may be prepared by reacting corresponding 2-hydroxymethyl thiazinobenzimidazole derivatives with corresponding reactive derivatives of carbonylic acid or halogenide or by reacting 2-p-toluenesulfonyloxymethyl-thiazinobenzimidazole derivatives with sodium azides, thiols, phenols or amines. The above thiazinobenzimidazole derivatives wherein X in OH may be prepared by reducing their corresponding 2-alkoxycarbonyl derivatives. Where X represents a p-toluenesulfonyloxy group, the thiazinobenzimidazole derivatives may be obtained by reacting corresponding 2-hydroxymethyl-thiazinobenzimidazole derivatives with p-toluenesulfonyl chloride.

Abstract: Novel substance M-9337 obtained by culturing Streptomyces antihaemolyticus is effective as an antitoxic substance for neutralizing toxins discharged from streptococci, staphylococci, tetanus or the like.